This announcement is made by Peijia Medical Limited (the “Company”, together with itssubsidiaries, the “Group”) on a voluntary basis to provide the shareholders of the Companyand potential investors with updated information in relation to the latest business and newproduct development progress of the Group.
The board (the “Board”) of directors (the “Directors”) of the Company is pleased toannounce that the Company has successfully completed the first patient implant in theGlobal Clinical Study of the MonarQ TTVR® system (the “System”). The procedure wasperformed by Dr. Raj Makkar, Associate Director of Smidt Heart Institute and Chief ofInterventional Cardiology, and his team at Cedars Sinai Hospital in Los Angeles, CA, U.S.The MonarQ TTVR® system is an innovative option specifically designed for treatingTricuspid Regurgitation.
The System has a unique biodynamic attachment system thatutilizes and preserves the heart’s natural motion to secure the implant to the native leaflets,distribute systolic loads, and minimize paravalvular leaks over a wide range of annulussizes.
Reference is made to the Company’s announcement dated June 10, 2021, regarding itsacquisition of the MonarQ Transcatheter Tricuspid Valve Replacement technology (the“Technology”) from inQB8 Medical Technologies, LLC when the Technology was stillin pre-clinical stages. The Company owns the global rights to this Technology and anyproducts developed therefrom. The successful completion of the first patient implant marksthe official launch of the Global Clinical Study, representing a significant milestone in theCompany’s Tricuspid Regurgitation pipeline development.
